Global News

Merck’s investigational Ebola vaccine shows 100% efficacy rate

Monday, August 3, 2015

Merck, (known as MSD outside the U.S. and Canada), has announced its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100% efficacy in an analysis of interim data from a phase III ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published online in The Lancet. [Read More]